The ADA’s 85th Scientific Sessions, taking place June 20–24 in Chicago, promise to mark a turning point in diabetes and obesity care. With a slate of late-breaking data releases, the spotlight is firmly on next-generation weight-loss treatments and transformative technologies in type 1 diabetes (T1D) management.
Obesity: From Weekly to Monthly Dosing, and Beyond
A major focus is on evolving weight-loss therapies that push beyond traditional GLP-1 receptor agonists (RAs). Highlights include:
CagriSema (Novo Nordisk): A novel dual-agonist therapy combining semaglutide with cagrilintide (amylin + calcitonin RA). This “multi-angle” approach could raise the ceiling on safe, effective weight loss.
MariTide (Amgen): A once-monthly GLP-1 RA that could redefine dosing convenience. Despite not reaching top-line expectations for weight loss, its monthly schedule could significantly improve adherence.
Orforglipron (Eli Lilly): A nonpeptide oral GLP-1 RA that doesn’t require refrigeration, offers food-independent dosing, and may be cheaper to manufacture. Full phase 3 data (ACHIEVE-1 trial) will be presented.
Bimagrumab + Semaglutide (BELIEVE trial): Tackles the challenge of lean mass loss by combining muscle-preserving bimagrumab with semaglutide. Aiming to enhance the quality of weight loss.
CagriSema (Novo Nordisk): A novel dual-agonist therapy combining semaglutide with cagrilintide (amylin + calcitonin RA). This “multi-angle” approach could raise the ceiling on safe, effective weight loss.